Perfluorooctanoic acid exposure is associated with elevated homocysteine and hypertension in US adults

Occupational and Environmental Medicine

Volumn 69, Issue 9, 2012, Pages 658-662

  Min, Jin Young ^a   Lee, Kyung Jong ^b   Park, Jae Beom ^b   Min, Kyoung Bok ^b  

^a Seoul National University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; PERFLUOROOCTANOIC ACID;

ADULT; ARTICLE; CARDIOTOXICITY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

ADULT; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; ENVIRONMENTAL EXPOSURE; FEMALE; FLUOROCARBONS; HAZARDOUS SUBSTANCES; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MALE; MIDDLE AGED; NUTRITION SURVEYS; OCTANOIC ACIDS; ODDS RATIO; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84865450467     PISSN: 13510711     EISSN: 14707926     Source Type: Journal    
DOI: 10.1136/oemed-2011-100288     Document Type: Article

References (38)

1. Prevedouros K, Cousins IT, Buck RC, et al. Sources, fate and transport of perfluorocarboxylates. Environ Sci Technol 2006;40:32-44. (Pubitemid 43069883)
2. Lau C, Anitole K, Hodes C, et al. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 2007;99:366-94. (Pubitemid 351753056)
3. Calafat AM, Kuklenyik Z, Reidy JA, et al. Serum concentrations of 11 polyfluoroalkyl compounds in the U.S. population: data from the national health and Nutrition examination survey (NHANES). Environ Sci Technol 2007;41:2237-42. (Pubitemid 46595180)
4. Kannan K, Corsolini S, Falandysz J, et al. Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol 2004;38:4489-95. (Pubitemid 39180470)
5. Kubwabo C, Vais N, Benoit FM. A pilot study on the determination of perfluorooctanesulfonate and other perfluorinated compounds in blood of Canadians. J Environ Monit 2004;6:540-5. (Pubitemid 38869581)
6. Sakr CJ, Kreckmann KH, Green JW, et al. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J Occup Environ Med 2007;49:1086-96. (Pubitemid 350287341)
7. Sakr CJ, Leonard RC, Kreckmann KH, et al. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate. J Occup Environ Med 2007;49:872-9. (Pubitemid 47254709)
8. Olsen GW, Zobel LR. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health 2007;81:231-46. (Pubitemid 47617455)
9. Steenland K, Fletcher T, Savitz DA. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ Health Perspect 2010;118:1100-8.
10. Steenland K, Tinker S, Shankar A, et al. Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA. Environ Health Perspect 2010;118:229-33.
11. Costa G, Sartori S, Consonni D. Thirty years of medical surveillance in perfluooctanoic acid production workers. J Occup Environ Med 2009;51:364-72.
12. Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect 2010;118:197-202.
13. Shankar A, Xiao J, Ducatman A. Perfluoroalkyl chemicals and elevated serum uric acid in US adults. Clin Epidemiol 2011;3:251-8.
14. Stamler J, Daviglus ML, Garside DB, et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284:311-18. (Pubitemid 30469857)
15. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
16. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American heart association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151.
17. Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ Res 2006;99:692-705. (Pubitemid 44498303)
18. O'Toole TE, Conklin DJ, Bhatnagar A. Environmental risk factors for heart disease. Rev Environ Health 2008;23:167-202.
19. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocysteine in with the Abbott IMx® analyzer. Clin Chem 1995;41:991-4.
20. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39 (2 Suppl 1):S1-266.
21. Instruction Manual, bio-Rad Quantaphase II Folate Radioassay Kit. Hercules, CA: Bio-Rad Laboratories, 1993.
22. Leonard RC, Kreckmann KH, Sakr CJ, et al. Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann Epidemiol 2008;18:15-22. (Pubitemid 350184346)
23. Sakr CJ, Symons JM, Kreckmann KH, et al. Ischaemic heart disease mortality study among workers with occupational exposure to ammonium perfluorooctanoate. Occup Environ Med 2009;66:699-703.
24. Lundin JI, Alexander BH, Olsen GW, et al. Ammonium perfluorooctanoate production and occupational mortality. Epidemiology 2009;20:921-8.
25. Shankar A, Xiao J, Ducatman A. Perfluoroalkyl chemicals and chronic kidney disease in US adults. Am J Epidemiol 2011;174:893-900.
26. Andersen ME, Butenhoff JL, Chang SC, et al. Perfluoroalkyl acids and related chemistriesetoxicokinetics and modes of action. Toxicol Sci 2008;102:3-14. (Pubitemid 351250465)
27. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-57.
28. Verhoef P, Kok FJ, Kruyssen DA, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:989-95. (Pubitemid 27209279)
29. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
30. Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994;7:7Se12S.
31. Fletcher T, Savitz D, Steenland K; C8 Science Panel. Status Report: Association of Perfluorooctanoic Acid (PFOA) and Perfluoroctanesulfonate (PFOS) with Lipids Among Adults in a Community with High Exposure to (PFOA). 2008. http://www.c8sciencepanel.org/pdfs/Status-Report-C8-and-lipids-Oct2008.pdf (accessed 31 Mar 2011).
32. Melzer D, Rice N, Depledge MH, et al. Association between serum perfluoroctanoic acid (PFOA) and thyroid disease in the NHANES study. Environ Health Perspect 2010;118:686-92.
33. Panaretakis T, Shabalina IG, Grandér D, et al. Reactive oxygen species and mitochondria mediate the induction of apoptosis in human hepatoma HepG2 cells by the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid. Toxicol Appl Pharmacol 2001;173:56-64. (Pubitemid 32480365)
34. Yao X, Zhong L. Genotoxic risk and oxidative DNA damage in HepG2 cells exposed to perfluorooctanoic acid. Mutat Res 2005;587:38-44. (Pubitemid 41503579)
35. Gori AM, Corsi AM, Fedi S, et al. A proinflammatory state is associated with hyperhomocysteinemia in the elderly. Am J Clin Nutr 2005;82:335-41.
36. Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281:2113-18. (Pubitemid 29264690)
37. Chambers JC, McGregor A, Jean-Marie J, et al. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999;99:1156-60. (Pubitemid 29120086)
38. Ceriello A. Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 2008;31(Suppl 2):S181-4.